Stem Cell Research Funding in California: C. Randal Mills, CIRM President & CEO
In December of 2015, the governing Board of the California Institute for Regenerative Medicine (CIRM) unanimously adopted a bold new strategic plan that seeks to make the most out of the Institute’s remaining time and resources. CIRM 2.0, as we call it, is intended to more effectively drive our mission of accelerating stem cell treatments to patients with unmet medical needs. But to be successful, we need you. In this video presentation, CIRM President and CEO C. Randal Mills gives an overview of the CIRM 2.0 funding process.